Biogen Q3 Revenue Rises 11% to $2.8 Billion; Raises EPS Guidance
Biogen reported Q3 2026 revenue of $2.8B, up 11% YoY, with non-GAAP EPS of $2.62. GAAP net loss was $20.6M due to transaction-related charges. The company raised its full-year non-GAAP EPS guidance to $12.20–$13.00. Growth was driven by its acquired Apellis products and strong performance from SPINRAZA, LEQEMBI, and SYFOVRE.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide fresh data for traders to reassess valuation and short‑term price direction.
Market read
The earnings release and guidance update are primary drivers for Biogen's stock movement and may influence biotech sector sentiment.
What to watch
Upcoming Phase 3 readouts for litifilimab and other candidates could add volatility beyond the guidance impact.
Background
Biogen's Q3 2026 earnings beat revenue expectations and included a modest EPS guidance lift, marking the first public disclosure of these figures.
Ticker impact
Biogen raised the lower end of its full-year non-GAAP diluted EPS guidance to $12.20 after reporting Q3 revenue up 11% to $2.8B.
potential upside as the market prices in the higher EPS guidance
The EPS guidance lift is a fresh, material piece of information for a large‑cap biotech, creating immediate trading impetus.
Market effects
May lift sentiment for the broader biotech sector as earnings beat and guidance raise signal strong pipeline progress.
U.S. markets could see modest gains in healthcare indices.
Limited to investors tracking U.S. biotech earnings; no direct global macro effect.
Counterpoint
If the guidance raise is modest relative to expectations, the stock could already be priced in, limiting upside.
Key entities
- companyBiogen Inc.
Large‑cap biotech company reporting Q3 results.
